Executives from U.S. drugmakers such as Regeneron Pharmaceuticals and Pfizer talked about the possible changes awaiting the industry under President-elect Donald Trump at the Forbes Healthcare Summit this week. After he was elected, pharmaceutical stocks surged as investors concluded the threat of action on drug pricing had lessened. Trump has said he wants to repeal […]
Pfizer Inc.
Adhezion Biomedical, Pfizer ink long-term supply deal
Adhezion Biomedical announced today that it inked a long-term supply deal with Pfizer (NYSE:PFE) for exclusive U.S. distribution rights for Adhezion’s topical skin adhesives. The Wyomissing, Pa.-based medical device company has a product family of 2-octyl cyanoacrylate adhesives designed to hold the edges of skin wounds together, for use after minimally invasive surgery and simple […]
Fresenius, Smiths in the hunt for Pfizer’s $1.5B infusion pump biz
Germany’s Fresenius (NYSE:FMS) and Britain’s Smiths Group (LON:SMIN) have emerged as the final bidders for Pfizer‘s (NYSE:PFE) infusion pump business, inherited via the Big Pharma’s September 2015 purchase of Hospira for $15 billion. The winning bid is expected to be around $1.5 billion, according to Reuters. Private equity firm Pamplona Capital Management was also interested and reportedly made a […]
Capsugel said to explore sale, IPO
Capsugel‘s private equity owner is said to be exploring a sale or initial public offering for the Pfizer (NYSE:PFE) spinout. A deal could value Capsugel, which makes hard capsules and drug delivery products, at more than $5 billion, Reuters reported, citing “people familiar with the matter.” Private equity shop KKR & Co. (NYSE:KKR) paid $2.38 billion for Capsugel […]
